Avidity Is The Mid-Cap Rising Star Of 2024 So Far

New modalities and potential best-in-class challengers have excited investors in 2024 to date, but companies whose drugs have underperformed on the market have been punished.

The world of mid-cap biotech is no stranger to share price volatility, but a handful of companies have enjoyed the upside, emerging as rising stars this year thanks to eye-catching early results.

A review of the sector’s mid-cap stocks (here confined to market caps of $1bn-$13bn) produces a clear winner in the...